Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data

Predicting toxicity-related Docetaxel discontinuation and survival in metastatic castration-resistant prostate cancer using open phase 3 trial data

Bibliographic Details
Main Authors:	A. Martini, A.B. Parikh, G. Gandaglia, N. Fossati, G. Fallara, F. Barletta, S. Scuderi, D. Robesti, D. Cannoletta, R. Leni, V. Cucchiara, C.A. Bravi, E. Mazzone, G. Rosiello, G. Basile, L. Nocera, A. Necchi, M. Moschini, J.P. Sfakianos, M.D. Galsky, W.K. Oh, C. Tsao, F. Montorsi, A. Briganti
Format:	Article
Language:	English
Published:	Elsevier 2020-10-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320355634

Similar Items

Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: results from the national cancer database
by: G. Sorce, et al.
Published: (2020-10-01)

The inverse correlation between obesity and mortality in patients with metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials
by: D. Cignoli, et al.
Published: (2020-10-01)

Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma: Results from the national cancer database
by: A. Martini, et al.
Published: (2020-07-01)

A prospective, randomized, phase 3 trial assessing the impact of early Dorsal Venous Complex (eDVC) ligation on urinary continence recovery after robot-assisted radical prostatectomy. Results of an interim analysis on early post-operative outcomes
by: F. Montorsi, et al.
Published: (2020-07-01)

A prospective, randomized, phase 3 trial assessing the impact of Early Dorsal Venous Complex (EDVC) ligation on urinary continence recovery after robot-assisted radical prostatectomy. results of an interim analysis on early post-operative outcomes
by: F. Montorsi, et al.
Published: (2020-10-01)

Are men with low risk prostate cancer but high PIRADS score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
by: A. Stabile, et al.
Published: (2020-07-01)

When to omit lymphadenectomy during radical prostatectomy in patients with clinical localized prostate cancer: A clinical net benefit analysis weighting staging accuracy, risk of morbidity and life expectancy
by: A. Larcher, et al.
Published: (2020-07-01)

The implementation of a prospective standardized postoperative complication system according to the EAU guidelines is associated with a decrease in the rate of adverse postoperative outcomes over time
by: G. Rosiello, et al.
Published: (2020-07-01)

Age and Gleason score upgrading between prostate biopsy and radical prostatectomy. Is this still true in the mp-MRI era?
by: F. Pellegrino, et al.
Published: (2020-10-01)

Focal therapy for prostate cancer: do apical lesions correlate with worse outcomes?
by: A. Stabile, et al.
Published: (2020-10-01)

Prognostic value of high PIRADS score lesions at mp-MRI of the prostate in men with low risk prostate cancer managed with active surveillance: Results from a single institution series
by: M. Bandini, et al.
Published: (2020-07-01)

Are men with low risk prostate cancer but high pirads score lesions at mp-MRI still candidate for active surveillance? Results from a large, multi-institutional radical prostatectomy series
by: F. Pellegrino, et al.
Published: (2020-10-01)

Initial negative multi-parametric MRI with concomitant negative biopsy: Are true negative findings confirmed over time? Results from a single institution series
by: A. Stabile, et al.
Published: (2020-07-01)

Initial negative multi-parametric MRI with concomitant negative biopsy: Are true negative findings confirmed over time? Results from a single institution series
by: E. Mazzone, et al.
Published: (2020-10-01)

Should we target all visible areas at mpMRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
by: F. Scalvi, et al.
Published: (2020-10-01)

A positive PSMA PET/CT Predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy
by: L. Nocera, et al.
Published: (2020-10-01)

A positive PSMA PET/CT predicts more aggressive disease progression in patients with biochemical recurrence after radical prostatectomy
by: D. Robesti, et al.
Published: (2020-07-01)

Multiparametric MRI of the prostate significantly underestimates tumor volume of small visible lesions. Implications for tailored focal therapy approaches
by: A. Stabile, et al.
Published: (2020-07-01)

Prognostic value of high PIRADS score lesions at mp-MRI of the prostate in men with low risk prostate cancer managed with active surveillance. results from a single institution series
by: G. Sorce, et al.
Published: (2020-10-01)

The impact of persistently elevated PSA levels on progression and survival of patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer
by: D. Cannoletta, et al.
Published: (2020-10-01)

Should we target all visible areas at mp-MRI suspicious for clinically significant prostate cancer in addition to the index lesion? Results from a two-institution series
by: A. Stabile, et al.
Published: (2020-07-01)

The relative drop of PSA values after androgen deprivation therapy is a useful parameter to select the best candidate for cytoreductive radical prostatectomy among patients with oligometastatic prostate cancer: an external validation study
by: E. Mazzone, et al.
Published: (2020-10-01)

Is focal ablation as effective as hemi-ablation? Analysis of treatment patterns over 12 years from a high volume centre for focal therapy
by: A. Stabile, et al.
Published: (2020-07-01)

How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series
by: A. Stabile, et al.
Published: (2020-07-01)

Radical prostatectomy versus radiotherapy in M1a and low volume M1b prostate cancer patients: an indirect comparison with the STAMPEDE trial arm H
by: G. Gandaglia, et al.
Published: (2020-10-01)

How can we increase the positive predictive value of PIRADS 4 and 5 lesions at mp-MRI? Development of a novel prediction tool relying on a large, multi-institutional series
by: F. Barletta, et al.
Published: (2020-10-01)

Association between BRCA 1/2 polymorphisms and disease aggressiveness in a prospective cohort of prostate cancer patients undergoing radical prostatectomy
by: V. Cucchiara, et al.
Published: (2020-07-01)

Is focal ablation as effective as hemi-ablation? analysis of treatment patterns over 12 years from a high volume centre for focal therapy
by: A. Stabile, et al.
Published: (2020-10-01)

Multiparametric MRI of the prostate significantly underestimates tumor volume of small visible lesions. Implications for tailored focal therapy approaches
by: F. Barletta, et al.
Published: (2020-10-01)

No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: Interim results from the PURE01 study
by: M. Bandini, et al.
Published: (2020-07-01)

Outcome of non-responders to neoadjuvant immunotherapy compared to cisplatin-based chemotherapy before radical cystectomy in muscle-invasive bladder cancer
by: M. Bandini, et al.
Published: (2020-07-01)

No-response at mpMRI after neoadjuvant pembrolizumab is a proxy of adverse pathological and oncological outcomes in patients treated with radical cystectomy: interim results from the PURE01 study
by: G. Basile, et al.
Published: (2020-10-01)

Association between BRCA 1/2 polymorphisms and disease aggressiveness in a prospective cohort of prostate cancer patients undergoing radical prostatectomy
by: V. Cucchiara, et al.
Published: (2020-10-01)

The relationship between percentage PSA reduction and rate of failure after focal therapy for prostate cancer
by: A. Stabile, et al.
Published: (2020-07-01)

Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended, of Course
by: Giorgio Gandaglia, et al.
Published: (2022-10-01)

Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: a stage-specific analysis from a large multi-institutional series
by: D. Robesti, et al.
Published: (2020-10-01)

Long-term outcomes of clinically node-positive prostate cancer patients treated with radical prostatectomy as part of a multimodal treatment: patterns of recurrence and impact on competing-risk mortality
by: D. Cannoletta, et al.
Published: (2020-10-01)

Assessing the impact of salvage radiation therapy field after radical prostatectomy: A long-term analysis from a large multi-institutional series
by: N. Fossati, et al.
Published: (2020-07-01)

Is whenever feasible-strategy for partial nephrectomy invariably justified? the impact of clinical tumour size on postoperative renal function
by: G. Fallara, et al.
Published: (2020-10-01)

Can we improve our ability to assess primary tumor stage of prostate cancer in patients with MRI-visible lesions? development and external validation of a novel T-stage classification based on clinical and MRI findings
by: L. Nocera, et al.
Published: (2020-10-01)